High-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Abu El Asrar, Ahmed M ^a   Nawaz, Mohd Imtiaz ^a   Siddiquei, Mohammad Mairaj ^a   Al Kharashi, Abdullah S ^a   Kangave, Dustan ^a   Mohammad, Ghulam ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 3; GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; SYNAPTOPHYSIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CILIARY DISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; VITREOUS BODY; WESTERN BLOTTING; ANIMAL; BLOOD; DRUG EFFECTS; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; SPRAGUE DAWLEY RAT; VERY ELDERLY; YOUNG ADULT; DRUG EFFECT;

RATTUS;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHEMOKINE CCL2; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCYRRHIZIC ACID; HMGB1 PROTEIN; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; YOUNG ADULT;

EID: 84878664920     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/863036     Document Type: Article

References (54)

1. Seki M., Tanaka T., Nawa H., Usui T., Fukuchi T., Ikeda K., Abe H., Takei N., Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 2004 53 9 2412 2419 2-s2.0-4344599833 10.2337/diabetes.53.9.2412 (Pubitemid 39145597)
2. Barber A. J., A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003 27 2 283 290 2-s2.0-0037376768 10.1016/S0278-5846(03)00023-X (Pubitemid 36351495)
3. Sasaki M., Ozawa Y., Kurihara T., Kubota S., Yuki K., Noda K., Kobayashi S., Ishida S., Tsubota K., Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia 2010 53 5 971 979 2-s2.0-77952089530 10.1007/s00125-009-1655-6
4. Abu El-Asrar A. M., Dralands L., Missotten L., Al-Jadaan I. A., Geboes K., Expression of apoptosis markers in the retinas of human subjects with diabetes. Investigative Ophthalmology and Visual Science 2004 45 8 2760 2766 2-s2.0-3242884227 10.1167/iovs.03-1392 (Pubitemid 38998875)
5. Zong H., Ward M., Stitt A. W., AGEs, RAGE, and diabetic retinopathy. Current Diabetes Reports 2011 11 4 244 252 10.1007/s11892-011-0198-7
6. Seki M., Nawa H., Fukuchi T., Abe H., Takei N., BDNF is upregulated by postnatal development and visual experience: quantitative and immunohistochemical analyses of BDNF in the rat retina. Investigative Ophthalmology and Visual Science 2003 44 7 3211 3218 2-s2.0-0037562428 10.1167/iovs.02-1089 (Pubitemid 36759794)
7. Martin K. R. G., Quigley H. A., Zack D. J., Levkovitch-Verbin H., Kielczewski J., Valenta D., Baumrind L., Pease M. E., Klein R. L., Hauswirth W. W., Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Investigative Ophthalmology and Visual Science 2003 44 10 4357 4365 2-s2.0-0141430092 10.1167/iovs.02-1332 (Pubitemid 37186270)
8. Binder D. K., Scharfman H. E., Brain-derived neurotrophic factor. Growth Factors 2004 22 3 123 131 2-s2.0-5744233877 10.1080/08977190410001723308 (Pubitemid 39377904)
9. van Beijnum J. R., Buurman W. A., Griffioen A. W., Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008 11 1 91 99 2-s2.0-41049117932 10.1007/s10456-008-9093-5
10. Treutiger C. J., Mullins G. E., Johansson A. S. M., Rouhiainen A., Rauvala H. M. E., Erlandsson-Harris H., Andersson U., Yang H., Tracey K. J., Andersson J., Palmblad J. E. W., High mobility group 1 B-box mediates activation of human endothelium. Journal of Internal Medicine 2003 254 4 375 385 2-s2.0-0141750710 10.1046/j.1365-2796.2003.01204.x (Pubitemid 37211261)
11. Fiuza C., Bustin M., Talwar S., Tropea M., Gerstenberger E., Shelhamer J. H., Suffredini A. F., Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003 101 7 2652 2660 2-s2.0-0037769813 10.1182/blood-2002-05-1300 (Pubitemid 36857626)
12. Luan Z. G., Zhang H., Yang P. T., Ma X. C., Zhang C., Guo R. X., HMGB1 activates nuclear factor- B signaling by RAGE and increases the production of TNF- α in human umbilical vein endothelial cells. Immunobiology 2010 215 12 956 962 2-s2.0-78049291345 10.1016/j.imbio.2009.11.001
13. Takeuchi M., Takino J. I., Yamagishi S. I., Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy. Current Drug Targets 2010 11 11 1468 1482 2-s2.0-79954991400
14. Yan S. F., Yan S. D., Ramasamy R., Schmidt A. M., Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Annals of Medicine 2009 41 6 408 422 2-s2.0-70349877740 10.1080/07853890902806576
15. Gao H. M., Zhou H., Zhang F., Wilson B. C., Kam W., Hong J. S., HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. Journal of Neuroscience 2011 31 3 1081 1092 2-s2.0-78751502344 10.1523/JNEUROSCI.3732-10.2011
16. Joussen A. M., Poulaki V., Le M. L., Koizumi K., Esser C., Janicki H., Schraermeyer U., Kociok N., Fauser S., Kirchhof B., Kern T. S., Adamis A. P., A central role for inflammation in the pathogenesis of diabetic retinopathy. The FASEB Journal 2004 18 12 1450 1452 2-s2.0-7044228789 10.1096/fj.03-1476fje (Pubitemid 39561611)
17. Miyamoto K., Khosrof S., Bursell S. E., Rohan R., Murata T., Clermont A. C., Aiello L. P., Ogura Y., Adamis A. P., Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proceedings of the National Academy of Sciences of the United States of America 1999 96 19 10836 10841 2-s2.0-0032863021 10.1073/pnas.96.19.10836 (Pubitemid 29442230)
18. Kim J. B., Joon S. C., Yu Y. M., Nam K., Piao C. S., Kim S. W., Lee M. H., Han P. L., Park J. S., Lee J. K., HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. Journal of Neuroscience 2006 26 24 6413 6421 2-s2.0-33745788420 10.1523/JNEUROSCI.3815-05.2006 (Pubitemid 44318322)
19. Kim I. D., Shin J. H., Kim S. W., Choi S., Ahn J., Han P. L., Park J. S., Lee J. K., Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Molecular Therapy 2012 20 829 839 10.1038/mt.2011.291
20. Kim S. W., Jin Y., Shin J. H., Kim I. D., Lee H. K., Park S., Han P. L., Lee J. K., Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiology of Disease 2012 46 1 147 156 10.1016/j.nbd.2011.12.056
21. Dvoriantchikova G., Hernandez E., Grant J., Santos A. R., Yang H., Ivanvov D., The high-mobility group box-1 nuclear factor mediates retinal injury after ischemia reperfusion. Investigative Ophthalmology & Visual Science 2011 52 7187 7194 10.1167/iovs.11-7793
22. Abu El-Asrar A. M., Nawaz M. I., Kangave D., Siddiquei M. M., Geboes K., Osteopontin and other regulators of angiogenesis and fibrogenesis in the vitreous from patients with proliferative vitreoretinal disorders. Mediators of Inflammation 2012 2012 8 493043 10.1155/2012/493043
23. Abu El-Asrar A. M., Nawaz M. I., Kangave D., Geboes K., Ola M. S., Ahmad S., Al-Shabrawey M., High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Molecular Vision 2011 17 1829 1838 2-s2.0-79960729070
24. Abu El-Asrar A. M., Missotten L., Geboes K., Expression of high-mobility groups box-1/receptor for advanced glycation end products/osteopontin/early growth response-1 pathway in proliferative vitreoretinal epiretinal membranes. Molecular Vision 2011 17 508 518 2-s2.0-79952145525
25. Mollica L., de Marchis F., Spitaleri A., Dallacosta C., Pennacchini D., Zamai M., Agresti A., Trisciuoglio L., Musco G., Bianchi M. E., Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chemistry & Biology 2007 14 431 441 10.1016/j.chembiol.2007.03.007 (Pubitemid 46617319)
26. Mohammad G., Siddiquei M. M., Othman A., Al-Shabrawey M., Abu El-Asrar A. M., High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Experimental Eye Research 2013 107 101 109 10.1016/j.exer.2012.12.009
27. Phillips H. S., Hains J. M., Armanini M., Laramee G. R., Johnson S. A., Winslow J. W., BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991 7 5 695 702 2-s2.0-0025993361 10.1016/0896-6273(91)90273-3
28. Yamanaka M., Itakura Y., Ono-Kishino M., Tsuchida A., Nakagawa T., Taiji M., Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice. Journal of Bioscience and Bioengineering 2008 105 4 395 402 2-s2.0-43549106361 10.1263/jbb.105.395 (Pubitemid 351680739)
29. Yamanaka M., Itakura Y., Tsuchida A., Nakagawa T., Noguchi H., Taiji M., Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice. Diabetes, Obesity and Metabolism 2007 9 6 879 888 2-s2.0-35048846963 10.1111/j.1463-1326.2006.00675.x (Pubitemid 47555209)
30. Krabbe K. S., Nielsen A. R., Krogh-Madsen R., Plomgaard P., Rasmussen P., Erikstrup C., Fischer C. P., Lindegaard B., Petersen A. M., Taudorf S., Secher N. H., Pilegaard H., Bruunsgaard H., Pedersen B. K., Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007 50 2 431 438 2-s2.0-34447127251 10.1007/s00125-006-0537-4
31. Fujinami A., Ohta K., Obayashi H., Fukui M., Hasegawa G., Nakamura N., Kozai H., Imai S., Ohta M., Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: relationship to glucose metabolism and biomarkers of insulin resistance. Clinical Biochemistry 2008 41 10-11 812 817 2-s2.0-44949212699 10.1016/j.clinbiochem.2008.03.003
32. Skrha J. Jr., Kalousovā M., Svarcovā J., Muravskā A., Kvasnička J., Landovā L., Zima T., Skrha J., Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes 2012 120 277 281 10.1055/s-0031-1283161
33. Nin J. W. M., Ferreira I., Schalkwijk C. G., Prins M. H., Chaturvedi N., Fuller J. H., Stehouwer C. D. A., Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 2009 52 4 705 714 2-s2.0-61449143384 10.1007/s00125-009-1263-5
34. Spiwoks-Becker I., Vollrath L., Seeliger M. W., Jaissle G., Eshkind L. G., Leube R. E., Synaptic vesicle alterations in rod photoreceptors of synaptophysin-deficient mice. Neuroscience 2001 107 1 127 142 2-s2.0-0035834813 10.1016/S0306-4522(01)00345-1 (Pubitemid 34020691)
35. VanGuilder H. D., Brucklacher R. M., Patel K., Ellis R. W., Freeman W. M., Barber A. J., Diabetes downregulates presynaptic proteins and reduces basal synapsin i phosphorylation in rat retina. European Journal of Neuroscience 2008 28 1 1 11 2-s2.0-54049107380 10.1111/j.1460-9568.2008.06322.x
36. Kurihara T., Ozawa Y., Nagai N., Shinoda K., Noda K., Imamura Y., Tsubota K., Okano H., Oike Y., Ishida S., Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 2008 57 8 2191 2198 2-s2.0-50949116171 10.2337/db07-1281
37. Challier M., Jacqueminet S., Benabdesselam O., Grimaldi A., Beaudeux J. L., Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clinical Chemistry 2005 51 9 1749 1750 2-s2.0-24144459068 10.1373/clinchem.2005.051961 (Pubitemid 41233122)
38. Tan K. C., Shiu S. W., Chow W. S., Leng L., Bucala R., Betteridge D. J., Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006 49 11 2756 2762 2-s2.0-33947408459 10.1007/s00125-006-0394-1
39. Nowak M., Wielkoszyński T., Marek B., Kos-Kudła B., Świtochowska E., Siemińska L., Kajdaniuk D., Głogowska- Szelag J., Nowak K., Blood serum levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy. Clinical and Experimental Medicine 2008 8 3 159 164 2-s2.0-51749103945 10.1007/s10238-008-0173-z
40. Kado S., Nagata N., Circulating intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 1999 46 2 143 148 2-s2.0-0032736216 10.1016/S0168-8227(99)00083-2 (Pubitemid 29509922)
41. Pham M. N., Hawa M. I., Roden M., Schernthaner G., Pozzilli P., Buzzetti R., Scherbaum W. A., Seissler J., Hunter S., Leslie R. D. G., Kolb H., Schloot N. C., Increased serum concentrations of adhesion molecules but not of chemokines in patients with type 2 diabetes compared with patients with type 1 diabetes and latent autoimmune diabetes in adult age: action LADA5. Diabetic Medicine 2012 29 4 470 478 10.1111/j.1464-5491.2011.03546.x
42. Raucci A., Cugusi S., Antonelli A., Barabino S. M., Monti L., Bierhaus A., Reiss K., Saftig P., Bianchi M. E., A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). The FASEB Journal 2008 22 10 3716 3727 2-s2.0-54049108485 10.1096/fj.08-109033
43. Nakamura K., Yamagishi S. I., Adachi H., Kurita-Nakamura Y., Matsui T., Yoshida T., Imaizumi T., Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Molecular Medicine 2007 13 3-4 185 189 2-s2.0-34250675234 10.2119/2006-00090.Nakamura (Pubitemid 46944961)
44. Yan S. F., Ramasamy R., Schmidt A. M., Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochemical Pharmacology 2010 79 10 1379 1386 2-s2.0-77649186801 10.1016/j.bcp.2010.01.013
45. Maillard-Lefebvre H., Boulanger E., Daroux M., Gaxatte C., Hudson B. I., Lambert M., Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology 2009 48 10 1190 1196 2-s2.0-70350774161
46. Kaji Y., Usui T., Ishida S., Yamashiro K., Moore T. C. B., Moore J., Yamamoto Y., Yamamoto H., Adamis A. P., Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Investigative Ophthalmology and Visual Science 2007 48 2 858 865 2-s2.0-33847765812 10.1167/iovs.06-0495 (Pubitemid 351260723)
47. Barile G. R., Pachydaki S. I., Tari S. R., Lee S. E., Donmoyer C. M., Ma W., Rong L. L., Buciarelli L. G., Wendt T., Hörig H., Hudson B. I., Qu W., Weinberg A. D., Yan S. F., Schmidt A. M., The RAGE axis in early diabetic retinopathy. Investigative Ophthalmology and Visual Science 2005 46 8 2916 2924 2-s2.0-24644508501 10.1167/iovs.04-1409 (Pubitemid 43086714)
48. Stranges S., Dorn J. M., Donahue R. P., Browne R. W., Freudenheim J. L., Hovey K. M., Trevisan M., Oxidation, type 2 diabetes, and coronary heart disease: a complex interaction: findings from a population-based study. Diabetes Care 2008 31 9 1864 1866 2-s2.0-56149116450 10.2337/dc08-0558
49. Turk H. M., Sevinc A., Camci C., Cigli A., Buyukberber S., Savli H., Bayraktar N., Plasma lipid peroxidation products and antioxidant enzyme activities in patients with type 2 diabetes mellitus. Acta Diabetologica 2002 39 3 117 122 2-s2.0-0036744927 10.1007/s005920200029
50. Hartnett M. E., Stratton R. D., Browne R. W., Rosner B. A., Lanham R. J., Armstrong D., Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care 2000 23 2 234 240 2-s2.0-0033979291 (Pubitemid 30071030)
51. Kowluru R. A., Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetologica 2001 38 4 179 185 2-s2.0-0035711473 10.1007/s592-001-8076-6 (Pubitemid 34145697)
52. Lechleitner M., Koch T., Herold M., Dzien A., Hoppichler F., Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. Journal of Internal Medicine 2000 248 1 67 76 2-s2.0-0033941219 10.1046/j.1365-2796. 2000.00705.x (Pubitemid 30470006)
53. Ceriello A., Falleti E., Motz E., Toboga C., Tonutti L., Ézsol Z., Gonano F., Bartoli E., Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Hormone and Metabolic Research 1998 30 3 146 149 2-s2.0-0031897387 (Pubitemid 28172522)
54. Yao D., Brownlee M., Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010 59 1 249 255 2-s2.0-77449142258 10.2337/db09-0801